This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

About PAMORAs

MOVENTIG (naloxegol) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).1

Definition of laxative inadequate responder (LIR): In the two weeks prior to first study visit patients had to have reported concurrent OIC symptoms of at least moderate severity while taking at least one laxative class for a minimum of four days during the pre-study period.1

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com

Click here for Prescribing Information.

PAMORAs as a treatment option for OIC

Opioid antagonist drugs can be helpful in relieving the symptoms of OIC, however drugs such as naloxone cross the blood-brain barrier and so can compromise pain control. Opioid antagonist drugs that primarily block opioid receptors in the GI tract can relieve the symptoms of OIC without diminishing pain control. This class of drugs is known as peripherally acting mu-opioid receptor antagonists (PAMORAs).1

Watch the video below to hear from expert speakers on PAMORAs as a treatment option for OIC. 

MOVENTIG (naloxegol) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). For advice on the responsible use of opioids to treat pain, please click here

Average:

  • References

    1. Farmer AD et al. UEG Journal. 2019;7(1):7-20.

    KKI/INT/KKI/0632 November 2023